325 related articles for article (PubMed ID: 19117990)
1. Distinct roles for mammalian target of rapamycin complexes in the fibroblast response to transforming growth factor-beta.
Rahimi RA; Andrianifahanana M; Wilkes MC; Edens M; Kottom TJ; Blenis J; Leof EB
Cancer Res; 2009 Jan; 69(1):84-93. PubMed ID: 19117990
[TBL] [Abstract][Full Text] [Related]
2. A critical role for the mTORC2 pathway in lung fibrosis.
Chang W; Wei K; Ho L; Berry GJ; Jacobs SS; Chang CH; Rosen GD
PLoS One; 2014; 9(8):e106155. PubMed ID: 25162417
[TBL] [Abstract][Full Text] [Related]
3. TGF-β Promotes Metabolic Reprogramming in Lung Fibroblasts via mTORC1-dependent ATF4 Activation.
O'Leary EM; Tian Y; Nigdelioglu R; Witt LJ; Cetin-Atalay R; Meliton AY; Woods PS; Kimmig LM; Sun KA; Gökalp GA; Mutlu GM; Hamanaka RB
Am J Respir Cell Mol Biol; 2020 Nov; 63(5):601-612. PubMed ID: 32668192
[TBL] [Abstract][Full Text] [Related]
4. Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors.
Huang J; Wu S; Wu CL; Manning BD
Cancer Res; 2009 Aug; 69(15):6107-14. PubMed ID: 19602587
[TBL] [Abstract][Full Text] [Related]
5. Insulin-like growth factor-I inhibits transcriptional responses of transforming growth factor-beta by phosphatidylinositol 3-kinase/Akt-dependent suppression of the activation of Smad3 but not Smad2.
Song K; Cornelius SC; Reiss M; Danielpour D
J Biol Chem; 2003 Oct; 278(40):38342-51. PubMed ID: 12876289
[TBL] [Abstract][Full Text] [Related]
6. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.
Feldman ME; Apsel B; Uotila A; Loewith R; Knight ZA; Ruggero D; Shokat KM
PLoS Biol; 2009 Feb; 7(2):e38. PubMed ID: 19209957
[TBL] [Abstract][Full Text] [Related]
7. The TSC1-TSC2 complex is required for proper activation of mTOR complex 2.
Huang J; Dibble CC; Matsuzaki M; Manning BD
Mol Cell Biol; 2008 Jun; 28(12):4104-15. PubMed ID: 18411301
[TBL] [Abstract][Full Text] [Related]
8. PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling.
Woo SY; Kim DH; Jun CB; Kim YM; Haar EV; Lee SI; Hegg JW; Bandhakavi S; Griffin TJ; Kim DH
J Biol Chem; 2007 Aug; 282(35):25604-12. PubMed ID: 17599906
[TBL] [Abstract][Full Text] [Related]
9. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility.
Gulati N; Karsy M; Albert L; Murali R; Jhanwar-Uniyal M
Int J Oncol; 2009 Oct; 35(4):731-40. PubMed ID: 19724909
[TBL] [Abstract][Full Text] [Related]
10. Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis.
Pollizzi K; Malinowska-Kolodziej I; Stumm M; Lane H; Kwiatkowski D
Mol Cancer; 2009 Jun; 8():38. PubMed ID: 19527517
[TBL] [Abstract][Full Text] [Related]
11. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1.
Thoreen CC; Kang SA; Chang JW; Liu Q; Zhang J; Gao Y; Reichling LJ; Sim T; Sabatini DM; Gray NS
J Biol Chem; 2009 Mar; 284(12):8023-32. PubMed ID: 19150980
[TBL] [Abstract][Full Text] [Related]
12. Protein kinase C and P2Y12 take center stage in thrombin-mediated activation of mammalian target of rapamycin complex 1 in human platelets.
Moore SF; Hunter RW; Hers I
J Thromb Haemost; 2014 May; 12(5):748-60. PubMed ID: 24612393
[TBL] [Abstract][Full Text] [Related]
13. Critical role of a survivin/TGF-β/mTORC1 axis in IGF-I-mediated growth of prostate epithelial cells.
Song K; Shankar E; Yang J; Bane KL; Wahdan-Alaswad R; Danielpour D
PLoS One; 2013; 8(5):e61896. PubMed ID: 23658701
[TBL] [Abstract][Full Text] [Related]
14. Renal tumours in a Tsc2(+/-) mouse model do not show feedback inhibition of Akt and are effectively prevented by rapamycin.
Yang J; Kalogerou M; Samsel PA; Zhang Y; Griffiths DF; Gallacher J; Sampson JR; Shen MH
Oncogene; 2015 Feb; 34(7):922-31. PubMed ID: 24632604
[TBL] [Abstract][Full Text] [Related]
15. CD40-induced signaling in human endothelial cells results in mTORC2- and Akt-dependent expression of vascular endothelial growth factor in vitro and in vivo.
Dormond O; Contreras AG; Meijer E; Datta D; Flynn E; Pal S; Briscoe DM
J Immunol; 2008 Dec; 181(11):8088-95. PubMed ID: 19018001
[TBL] [Abstract][Full Text] [Related]
16. Site-specific mTOR phosphorylation promotes mTORC1-mediated signaling and cell growth.
Acosta-Jaquez HA; Keller JA; Foster KG; Ekim B; Soliman GA; Feener EP; Ballif BA; Fingar DC
Mol Cell Biol; 2009 Aug; 29(15):4308-24. PubMed ID: 19487463
[TBL] [Abstract][Full Text] [Related]
17. PI3K/mTOR signaling regulates prostatic branching morphogenesis.
Ghosh S; Lau H; Simons BW; Powell JD; Meyers DJ; De Marzo AM; Berman DM; Lotan TL
Dev Biol; 2011 Dec; 360(2):329-42. PubMed ID: 22015718
[TBL] [Abstract][Full Text] [Related]
18. RAD 001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia.
Mancini M; Petta S; Martinelli G; Barbieri E; Santucci MA
J Cell Biochem; 2010 Feb; 109(2):320-8. PubMed ID: 20014066
[TBL] [Abstract][Full Text] [Related]
19. mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action.
Soliman GA; Acosta-Jaquez HA; Dunlop EA; Ekim B; Maj NE; Tee AR; Fingar DC
J Biol Chem; 2010 Mar; 285(11):7866-79. PubMed ID: 20022946
[TBL] [Abstract][Full Text] [Related]
20. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]